PMID- 35069970
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2022
DP  - 2022
TI  - Notoginsenoside R1 Facilitated Wound Healing in High-Fat 
      Diet/Streptozotocin-Induced Diabetic Rats.
PG  - 2476493
LID - 10.1155/2022/2476493 [doi]
LID - 2476493
AB  - Diabetic ulcers bring about high morbidity and mortality in patients and cause a 
      great economic burden to society as a whole. Since existing treatments cannot 
      fulfil patient requirements, it is urgent to find effective therapies. In this 
      study, the wound healing effect of topical notoginsenoside R1 (NR1) treatment on 
      diabetic full-thickness wounds in type II diabetes mellitus (T2DM) was induced by 
      the combination of a high-fat diet and streptozotocin (STZ) injection. NR1 
      significantly increased the wound closure rate, enhanced extracellular matrix 
      (ECM) secretion, promoted collagen growth, increased platelet endothelial cell 
      adhesion molecule-1 (CD31) expression, and decreased cleaved caspase-3 
      expression. RNA-Seq analysis identified ECM remodeling and inflammation as 
      critical biological processes and Timp1 and Mmp3 as important targets in 
      NR1-mediated wound healing. Further experiments showed that NR1-treated wounds 
      demonstrated higher expression of tissue inhibitor of metalloproteinase 1 (TIMP1) 
      and transforming growth factor-beta1 (TGFbeta1) and lower expression of matrix 
      metallopeptidase 9 (MMP9), matrix metallopeptidase 3 (MMP3), interleukin-1beta 
      (IL-1beta), and interleukin-6 (IL-6) than diabetic wounds. These investigations 
      promote the understanding of the mechanism of NR1-mediated diabetic wound healing 
      and provide a promising therapeutic drug to enhance diabetic wound healing.
CI  - Copyright (c) 2022 Guangzhao Cao et al.
FAU - Cao, Guangzhao
AU  - Cao G
AUID- ORCID: 0000-0003-0039-6888
AD  - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 
      Beijing 100700, China.
FAU - Xiang, Changpei
AU  - Xiang C
AUID- ORCID: 0000-0002-9210-9403
AD  - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 
      Beijing 100700, China.
FAU - Zhou, Rui
AU  - Zhou R
AUID- ORCID: 0000-0003-1109-9248
AD  - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 
      Beijing 100700, China.
FAU - Zhang, Yi
AU  - Zhang Y
AUID- ORCID: 0000-0003-2783-0998
AD  - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 
      Beijing 100700, China.
FAU - Xu, He
AU  - Xu H
AUID- ORCID: 0000-0001-5494-9236
AD  - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 
      Beijing 100700, China.
FAU - Yang, Hongjun
AU  - Yang H
AUID- ORCID: 0000-0001-5501-3288
AD  - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 
      Beijing 100700, China.
FAU - Zhang, Jingjing
AU  - Zhang J
AUID- ORCID: 0000-0002-1349-9184
AD  - Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, 
      Beijing 100700, China.
AD  - Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 
      100700, China.
LA  - eng
PT  - Journal Article
DEP - 20220113
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Ginsenosides)
RN  - 5W494URQ81 (Streptozocin)
RN  - Z62692362Z (notoginsenoside R1)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Experimental/*complications/*drug therapy
MH  - Diabetic Angiopathies/*drug therapy
MH  - Diet, High-Fat/*adverse effects
MH  - Ginsenosides/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Panax/*chemistry
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin/*adverse effects
MH  - Ulcer/*drug therapy
MH  - Wound Healing/*drug effects
PMC - PMC8777460
COIS- The authors declare no conflicts of interest.
EDAT- 2022/01/25 06:00
MHDA- 2022/03/09 06:00
PMCR- 2022/01/13
CRDT- 2022/01/24 08:50
PHST- 2021/05/14 00:00 [received]
PHST- 2021/11/03 00:00 [accepted]
PHST- 2022/01/24 08:50 [entrez]
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2022/01/13 00:00 [pmc-release]
AID - 10.1155/2022/2476493 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2022 Jan 13;2022:2476493. doi: 10.1155/2022/2476493. 
      eCollection 2022.